CervoMed Shares Rise 15% on FDA's Orphan Drug Designation for Neflamapimod

Dow Jones

2024/11/27

By Denny Jacob

CervoMed shares rose 15% after receiving the Food and Drug Administration's orphan drug designation for neflamapimod, its frontotemporal dementia treatment.

Shares were trading around $9.19. The stock is up 4.6% on the year.

The clinical-stage company said it's in discussions regarding the design of a proof-of-principle study while also continuing to prepare to advance neflamapimod into a Phase 3 trial in mid-2025.

Frontotemporal dementia is rare neurodegenerative disease that affects an estimated 50,000 to 60,000 people in the United States, roughly 110,000 in the European Union, with potentially higher prevalence in Asia and Latin America, said CervoMed.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

November 27, 2024 08:19 ET (13:19 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2486821378"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486821378\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2486821378?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486821378","market":"sg","top_or_hot":-1,"title":"CervoMed Shares Rise 15% on FDA's Orphan Drug Designation for Neflamapimod","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> shares rose 15% after receiving the Food and Drug Administration's orphan drug designation for neflamapimod, its frontotemporal dementia treatment. \n</p>\n<p>\n  Shares were trading around $9.19. The stock is up 4.6% on the year. \n</p>\n<p>\n  The clinical-stage company said it's in discussions regarding the design of a proof-of-principle study while also continuing to prepare to advance neflamapimod into a Phase 3 trial in mid-2025. \n</p>\n<p>\n  Frontotemporal dementia is rare neurodegenerative disease that affects an estimated 50,000 to 60,000 people in the United States, roughly 110,000 in the European Union, with potentially higher prevalence in Asia and Latin America, said CervoMed. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 27, 2024 08:19 ET (13:19 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CervoMed Shares Rise 15% on FDA's Orphan Drug Designation for Neflamapimod</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCervoMed Shares Rise 15% on FDA's Orphan Drug Designation for Neflamapimod\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-11-27 21:19</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> shares rose 15% after receiving the Food and Drug Administration's orphan drug designation for neflamapimod, its frontotemporal dementia treatment. \n</p>\n<p>\n  Shares were trading around $9.19. The stock is up 4.6% on the year. \n</p>\n<p>\n  The clinical-stage company said it's in discussions regarding the design of a proof-of-principle study while also continuing to prepare to advance neflamapimod into a Phase 3 trial in mid-2025. \n</p>\n<p>\n  Frontotemporal dementia is rare neurodegenerative disease that affects an estimated 50,000 to 60,000 people in the United States, roughly 110,000 in the European Union, with potentially higher prevalence in Asia and Latin America, said CervoMed. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 27, 2024 08:19 ET (13:19 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVO","symbol_name":"CervoMed","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2486821378","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486821378","pubTimestamp":1732713540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"CervoMed shares rose 15% after receiving the Food and Drug Administration's orphan drug designation for neflamapimod, its frontotemporal dementia treatment.Shares were trading around $9.19. The stock is up 4.6% on the year.The clinical-stage company said it's in discussions regarding the design of a proof-of-principle study while also continuing to prepare to advance neflamapimod into a Phase 3 trial in mid-2025.Frontotemporal dementia is rare neurodegenerative disease that affects an estimated 50,000 to 60,000 people in the United States, roughly 110,000 in the European Union, with potentially higher prevalence in Asia and Latin America, said CervoMed.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRVO":"CervoMed","BK4139":"生物科技"},"translate_title":"FDA授予Neflamapimod孤儿药称号，CervoMed股价上涨15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVO":1},"content_text":"By Denny Jacob \n\n\n \n\n\nCervoMed shares rose 15% after receiving the Food and Drug Administration's orphan drug designation for neflamapimod, its frontotemporal dementia treatment. \n\n\n  Shares were trading around $9.19. The stock is up 4.6% on the year. \n\n\n  The clinical-stage company said it's in discussions regarding the design of a proof-of-principle study while also continuing to prepare to advance neflamapimod into a Phase 3 trial in mid-2025. \n\n\n  Frontotemporal dementia is rare neurodegenerative disease that affects an estimated 50,000 to 60,000 people in the United States, roughly 110,000 in the European Union, with potentially higher prevalence in Asia and Latin America, said CervoMed. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 27, 2024 08:19 ET (13:19 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}